Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02093403 · ClinicalTrials.gov registry record · Phase 1
Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Bhavana Bhatnagar.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02093403 is a Phase 1 study that has completed, run by Bhavana Bhatnagar. The registered enrollment target is 25 participants.
The verdict
NCT02093403, a Phase 1 study, has completed, sponsored by Bhavana Bhatnagar.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of Selinexor when given together with decitabine in treating patients with acute myeloid leukemia that has returned after treatment (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as decitabine and Selinexor, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG decitabine
- DRUG selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-11-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02093403
The ClinicalTrials.gov registry entry for NCT02093403 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bhavana Bhatnagar, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02093403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02093403 about?
NCT02093403 is a clinical study titled "Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". This phase I trial studies the side effects and best dose of Selinexor when given together with decitabine in treating patients with acute myeloid leukemia that has returned after treatment (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as decitabine and S...
What is the current status of trial NCT02093403?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2014-03. Estimated completion is 2016-11-26.
What interventions are being tested in trial NCT02093403?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), decitabine (DRUG), selinexor (DRUG).
Who is sponsoring clinical trial NCT02093403?
This trial is sponsored by Bhavana Bhatnagar, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.